2016—2022年中国急性缺血性卒中静脉溶栓趋势及阿替普酶与尿激酶静脉溶栓院内结局比较分析

doi:10.3969/j.issn.1673-5765.2023.10.015

摘要/Abstract

摘要： 目的评估我国2016—2022年发病6 h内急性缺血性卒中患者静脉溶栓的变化趋势，并比较rt-PA与尿激酶静脉溶栓的院内临床结局差异。
方法纳入中国卒中中心联盟（Chinese Stroke Center Alliance，CSCA）2016年1月—2022年12月登记的发病6 h内到院的急性缺血性卒中患者555 991例，计算各年份rt-PA静脉溶栓和尿激酶静脉溶栓的比例变化。采用多因素logistic回归法，以rt-PA溶栓为对照，分析尿激酶溶栓对院内脑梗死出血转化、院内死亡及出院时良好神经功能结局（mRS评分0～1分）的影响。
结果分别有113 521例和30 950例患者进行了rt-PA和尿激酶静脉溶栓，溶栓率分别为20.42%和5.57%。从2016年至2022年，rt-PA静脉溶栓率从11.26%逐年递增至30.19%，而尿激酶静脉溶栓率则始终波动在较低水平。多因素logistic回归分析显示，与rt-PA静脉溶栓相比，尿激酶静脉溶栓患者发生脑梗死后出血转化（OR 0.740，95%CI 0.662～0.827，P＜0.01）和院内死亡的风险较低（OR 0.820，95%CI 0.764～0.881，P＜0.01），但两组患者出院时良好功能结局率无显著差异（OR 0.989，95%CI 0.951～1.028，P=0.57）。
结论 2016—2022年期间，我国发病6 h内到院的急性缺血性卒中患者rt-PA静脉溶栓率呈逐年增长趋势；尿激酶溶栓后发生脑梗死出血转化风险及院内死亡风险可能低于rt-PA静脉溶栓。

文章导读： 本文基于中国卒中中心联盟登记研究，发现2016—2022年间我国AIS rt-PA静脉溶栓率呈递增趋势，且相较于rt-PA静脉溶栓，尿激酶静脉溶栓后发生脑梗死出血转化风险及院内死亡风险可能较低。

关键词: 卒中; 静脉溶栓; rt-PA; 尿激酶; 院内结局

Abstract: Objective To investigate the temporal trend of intravenous thrombolysis in patients with acute ischemic stroke (AIS) who arrived within 6 hours after onset from 2016 to 2022 in China, and compare the risks of in-hospital outcomes between rt-PA and urokinase thrombolysis.
Methods A total of 555 991 AIS patients who arrived within 6 hours after onset were enrolled in the Chinese Stroke Center Alliance (CSCA) from January 2016 to December 2022. The rates of rt-PA and urokinase intravenous thrombolysis in AIS patients within 6 hours after onset were calculated respectively of each year. Multivariate logistic regression was used to analyze the risks of hemorrhagic transformation, in-hospital death and good functional outcome at discharge (mRS score 0-1) of urokinase thrombolysis group compared with rt-PA group.
Results 113 521 and 30 950 patients were treated with rt-PA and urokinase intravenous thrombolytic therapy respectively. The thrombolysis rates of rt-PA and urokinase were 20.42% and 5.57% respectively. From 2016 to 2022, the rt-PA intravenous thrombolysis rate increased from 11.26% to 30.19%, while the urokinase thrombolysis rate fluctuated at a low level. Multivariate logistic regression analysis showed that compared with rt-PA intravenous thrombolytic therapy, patients with urokinase intravenous thrombolytic therapy had a lower risk of hemorrhagic transformation (OR 0.740, 95%CI 0.662-0.827, P<0.01) and in-hospital death (OR 0.820, 95%CI 0.764-0.881, P<0.01). There was no significant difference in the rate of good functional outcome at discharge between the two groups (OR 0.989, 95%CI 0.951-1.028, P=0.57).
Conclusions The rate of rt-PA intravenous thrombolysis in AIS patients who arrived within 6 hours after onset increased year by year from 2016 to 2022. The risk of hemorrhagic transformation and in-hospital death after urokinase thrombolysis may be lower than that of rt-PA intravenous thrombolysis.

Key words: Stroke; Intravenous thrombolysis; rt-PA; Urokinase; In-hospital outcomes

宗黎霞, 谷鸿秋, 杨昕, 姜英玉, 李子孝, 王春娟. 2016—2022年中国急性缺血性卒中静脉溶栓趋势及阿替普酶与尿激酶静脉溶栓院内结局比较分析[J]. 中国卒中杂志, 2023, 18(10): 1202-1208.

ZONG Lixia, GU Hongqiu, YANG Xin, JIANG Yingyu, LI Zixiao, WANG Chunjuan. Trend of Intravenous Thrombolysis and a Comparative Analysis of In-hospital Outcomes of Intravenous Thrombolysis with Alteplase or Urokinase in Acute Ischemic Stroke in China from 2016 to 2022[J]. Chinese Journal of Stroke, 2023, 18(10): 1202-1208.

参考文献

[1] 王拥军，李子孝，谷鸿秋，等. 中国卒中报告2020（中文版）（1）[J]. 中国卒中杂志，2022，17（5）：433-447.
WANG Y J，LI Z X，GU H Q，et al. China Stroke Statistics 2020（1）[J]. Chin J Stroke，2022，17（5）：433-447.
[2] FRIEDMAN H S，KOROSHETZ W J，QURESHI N，et al. Tissue plasminogen activator for acute ischemic stroke[J]. N Engl J Med，1995，333（24）：1581-1587.
[3] HACKE W，KASTE M，BLUHMKI E，et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke[J]. N Engl J Med，2008，359（13）：1317-1329.
[4] WARDLAW J M，MURRAY V，BERGE E，et al. Recombinant tissue plasminogen activator for acute ischaemic stroke：an updated systematic review and meta-analysis[J]. The Lancet，2012，379（9834）：2364-2372.
[5] POWERS W J，RABINSTEIN A A，ACKERSON T，et al. Guidelines for the early management of patients with acute ischemic stroke：2019 update to the 2018 guidelines for the early management of acute ischemic stroke：a guideline for healthcare professionals from the American Heart Association/American Stroke Association[J/OL]. Stroke，2019，50（12）：e344-e418[2023-03-10]. https://doi：10.1161/STR.0000000000000211.
[6] BERGE E，WHITELEY W，AUDEBERT H，et al. European Stroke Organisation（ESO）guidelines on intravenous thrombolysis for acute ischaemic stroke[J/OL]. Eur Stroke J，2021，6（1）：I-LXII[2023-03-10]. https://doi：10.1177/2396987321989865.
[7] LIU L P，CHEN W Q，ZHOU H Y，et al. Chinese Stroke Association guidelines for clinical management of cerebrovascular disorders：executive summary and 2019 update of clinical management of ischemic cerebrovascular diseases[J]. Stroke Vasc Neurol，2020，5（2）：159-176.
[8] LI Z X，WANG C J，ZHAO X Q，et al. Substantial progress yet significant opportunity for improvement in stroke care in China[J]. Stroke，2016，47（11）：2843-2849.
[9] YIP W，FU H Q，CHEN A T，et al. 10 years of health-care reform in China：progress and gaps in universal health coverage[J]. Lancet，2019，394（10204）：1192-1204.
[10] WU S M，WU B，LIU M，et al. Stroke in China：advances and challenges in epidemiology，prevention，and management[J]. Lancet Neurol，2019，18（4）：394-405.
[11] WANG Y L，LI Z X，ZHAO X Q，et al. Effect of a multifaceted quality improvement intervention on hospital personnel adherence to performance measures in patients with acute ischemic stroke in China：a randomized clinical trial[J]. JAMA，2018，320（3）：245-254.
[12] WANG Y J，LI Z X，WANG Y L，et al. Chinese Stroke Center Alliance：a national effort to improve healthcare quality for acute stroke and transient ischaemic attack：rationale，design and preliminary findings[J]. Stroke Vasc Neurol，2018，3（4）：256-262.
[13] ZHONG W S，LIN L T，GONG X X，et al. Evaluation of a multicomponent intervention to shorten thrombolytic door-to-needle time in stroke patients in China（MISSION）：a cluster-randomized controlled trial[J/OL]. PLoS Med，2022，19（7）：e1004034[2023-03-10]. https://doi.org/10.1371/journal.pmed.1004034.
[14] LI Z X，WANG C J，ZHANG X M，et al. Rationale and design of a stepped wedge cluster randomised trial to improve acute reperfusion treatment quality for stroke：IMPROVE stroke care in China[J]. Stroke Vasc Neurol，2022，7（5）：451-456.
[15] 国家卫生健康委员会. 2019中国卫生健康统计年鉴[M]. 北京：中国协和医科大学出版社，2019：1-21.
National Health Commission of the People’s Republic of China. China Health Statistical Yearbook 2019[M]. Beijing：Peking Union Medical College Press，2019：1-21.
[16] YUSUF S，COLLINS R，PETO R，et al. Intravenous and intracoronary fibrinolytic therapy in acute myocardial infarction：overview of results on mortality，reinfarction and side-effects from 33 randomized controlled trials[J]. Eur Heart J，1985，6（7）：556-585.
[17] 国家“九五”攻关课题协作组. 急性脑梗死六小时以内的静脉溶栓治疗[J]. 中华神经科杂志，2002，35（4）：210-213.
National "Ninth Five-Year Plan" task group. Intravenous thrombolysis with urokinase for acute cerebral infarctions[J]. Chin J Neurol，2002，35（4）：210-213.
[18] 钟介石，刘松，朱榆红，等. 尿激酶溶栓后出血及早期神经功能恶化危险因素的多中心研究[J/OL]. 中华脑血管病杂志（电子版），2021，15（3）：163-169[2023-03-10]. https://zhnxgbzz.cma-cmc.com.cn/CN/10.11817/j.issn.1673-9248.2021.03.006.
ZHONG J S，LIU S，ZHU Y H，et al. Risk factors for bleeding and early neurological deterioration after urokinase thrombolysis：a retrospective multicenter study[J/OL]. Chin J Cerebrovasc Dis（Electronic Edition），2021，15（3）：163-169[2023-03-10]. https://zhnxgbzz.cma-cmc.com.cn/CN/10.11817/j.issn.1673-9248.2021.03.006.
[19] 陈永祥. 用阿替普酶与尿激酶对急性缺血性脑卒中患者进行静脉溶栓治疗的效果对比[J]. 当代医药论丛，2020，18（7）：130-131.
CHEN Y X. Effect comparison of intravenous thrombolytic therapy with alteplase and urokinase in patients with acute ischemic stroke[J]. Contemporary Medical Symposium，2020，18（7）：130-131.